Ziming Li

West Huaihai Road 241
Huaihai, 200030, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications

SYS6010, epidermal growth factor receptor-targeting antibody-drug conjugate for advanced non-small cell lung cancer: A phase 1 trial.

SYS6010, epidermal growth factor receptor-targeting antibody-drug conjugate for advanced non-small cell lung cancer: A phase 1 trial.

Journal: Cancer cell
Published: November 25, 2025

BCG-trained macrophages promote pan-anti-tumor activity through epigenetic rewiring of NOX2-ROS axis.

BCG-trained macrophages promote pan-anti-tumor activity through epigenetic rewiring of NOX2-ROS axis.

Journal: Journal of experimental & clinical cancer research : CR
Published: November 02, 2025

MYBL2 impedes cisplatin sensitivity through suppressing GSDME-mediated pyroptosis in lung adenocarcinoma.

MYBL2 impedes cisplatin sensitivity through suppressing GSDME-mediated pyroptosis in lung adenocarcinoma.

Journal: Cell death discovery
Published: September 14, 2025

NLRP4 unlocks an NK/macrophages-centered ecosystem to suppress non-small cell lung cancer.

NLRP4 unlocks an NK/macrophages-centered ecosystem to suppress non-small cell lung cancer.

Journal: Biomarker research
Published: October 04, 2024

Interferon-γ-stimulated antigen-presenting cancer-associated fibroblasts hinder neoadjuvant chemoimmunotherapy efficacy in lung cancer.

Interferon-γ-stimulated antigen-presenting cancer-associated fibroblasts hinder neoadjuvant chemoimmunotherapy efficacy in lung cancer.

Journal: Cell reports. Medicine
Published: July 06, 2024

Clinical benefit evaluation of drug treatment regimens for advanced lung cancer:based on ASCO-VF and ESMO-MCBS.

Clinical benefit evaluation of drug treatment regimens for advanced lung cancer:based on ASCO-VF and ESMO-MCBS.

Journal: Lung cancer (Amsterdam, Netherlands)
Published: April 28, 2024

ASO Video Abstract: Neoadjuvant Chemo-Immunotherapy Increases Tumor Immune Lymphocytes Infiltration in Resectable NSCLC.

ASO Video Abstract: Neoadjuvant Chemo-Immunotherapy Increases Tumor Immune Lymphocytes Infiltration in Resectable NSCLC.

Journal: Annals of surgical oncology
Published: August 24, 2023

ASO Author Reflections: Immune Microenvironment Indicators in Neoadjuvant Chemo-Immunotherapy.

ASO Author Reflections: Immune Microenvironment Indicators in Neoadjuvant Chemo-Immunotherapy.

Journal: Annals of surgical oncology
Published: July 28, 2023

Neoadjuvant Chemoimmunotherapy Increases Tumor Immune Lymphocytes Infiltration in Resectable Non-small Cell Lung Cancer.

Neoadjuvant Chemoimmunotherapy Increases Tumor Immune Lymphocytes Infiltration in Resectable Non-small Cell Lung Cancer.

Journal: Annals of surgical oncology
Published: November 22, 2022

FGFR1 promotes tumor immune evasion via YAP-mediated PD-L1 expression upregulation in lung squamous cell carcinoma.

FGFR1 promotes tumor immune evasion via YAP-mediated PD-L1 expression upregulation in lung squamous cell carcinoma.

Journal: Cellular immunology
Published: April 07, 2022

Brief analysis on pivot effect of Tianshu (ST 25)

Brief analysis on pivot effect of Tianshu (ST 25)

Journal: Zhongguo zhen jiu = Chinese acupuncture & moxibustion
Published: January 08, 2021

FGF2/FGFR1 regulates autophagy in FGFR1-amplified non-small cell lung cancer cells.

FGF2/FGFR1 regulates autophagy in FGFR1-amplified non-small cell lung cancer cells.

Journal: Journal of experimental & clinical cancer research : CR
Published: February 16, 2017
Showing 1-12 of 16

Last Updated: 09/26/2026